TANK-binding kinase 1 (TBK1) plays a key role in various cellular processes and, consequentially, in the pathophysiology of many diseases, from autoimmune diseases to viral infections. While TBK1 has seen increasing amounts of research in the past two decades, there are currently no available FDA-approved TBK1 inhibitors on the market due to safety, efficacy, and resource concerns.  

In this CAS Insights^TM report, we study the landscape of TBK1 through the lens of the CAS Content Collection^TM and investigate whether QSAR computer modeling – using chemical structures, the experimental activity of existing chemicals, and mathematical tools to predict the activity of new chemicals — can accelerate the development of effective TBK1 inhibitors.